ReviewClinical ophthalmology (Auckland, N.Z.)2018
How to minimize pterygium recurrence rates: clinical perspectives.
Review in Clinical ophthalmology (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04075227 (A Randomized Clinical Trial), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Clinical Trial: Comparison of the Efficacy of Topical 0.2% Loteprednol Etabonate and Topical 0.1% Dexamethasone in Impending Recurrent Pterygium
Who cites it
38 citing papers in PubMed, 97 citations in OpenAlex.
- Application of platelet-rich fibrin membrane versus amniotic membrane graft transplantation after pterygium excision: a randomised clinical trial.Eye (London, England) · 2026Trial
- Comparison of postoperative topical interferon-α2b versus intraoperative mitomycin C for pterygium recurrence prevention: a randomized clinical trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Trial
- Effect of multiple subconjunctival conbercept injections as an adjuvant to the surgical treatment of pterygium: a prospective randomised comparative 6-month follow-up study.Eye (London, England) · 2020Trial
- Proteomic and Clinical Characterization of Active vs. Quiescent Pterygium With Elevated Thrombospondin-1.Translational vision science & technology · 2026Article
- Complement C5a Promotes Epithelial-Mesenchymal Transition in Pterygium via C5aR Activation.Investigative ophthalmology & visual science · 2026Article
- The effectiveness of 0.05% cyclosporine A combined with deproteinized calf blood extract eye gel in the treatment of dry eye disease after pterygium surgery.Frontiers in medicine · 2026Article
- Comparison of Recurrence Rate and Outcomes of Pterygium Surgery with Inferior Versus Superior Rotational Conjunctival Flap: A Randomized Clinical Trial.Journal of ophthalmic & vision research · 2026Article
- Therapeutic Potential of Graphene Quantum Dots on Pterygium Cells.Investigative ophthalmology & visual science · 2025Article
- Effects of ranibizumab on microvasculature, oxidative stress and recurrence in primary pterygium surgery.International ophthalmology · 2025Article
- Modified protocol for pterygium surgery without blades and electrocoagulation.Frontiers in medicine · 2025Article
- Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.Scientific reports · 2024Article
- Comparison of the effects of 0.05% topical cyclosporine A versus 0.1% topical cyclosporine A on recurrence and clinical parameters following pterygium surgery.Turkish journal of medical sciences · 2024Article
- Application of topical 2% cyclosporine A in inflammatory ocular surface diseases.International ophthalmology · 2023Article
- The role of HPV in the etiopathogenesis of pterygium and the relationship with recurrence.International ophthalmology · 2023Article
- Conjunctival and Limbal Conjunctival Autograft vs. Amniotic Membrane Graft in Primary Pterygium Surgery: A 30-Year Comprehensive Review.Ophthalmology and therapy · 2023Review
- Double Flip Technique for Graft Transfer in Autograft Pterygium Surgery.Turkish journal of ophthalmology · 2023Article
- Autologous simple conjunctival epithelial transplantation for primary pterygium.International ophthalmology · 2022Article
- Evaluating the Efficacy and Safety of Different Pterygium Surgeries: A Review of the Literature.International journal of environmental research and public health · 2022Review
- Matrix Metalloproteinase-14 as an Instigator of Fibrosis in Human Pterygium and Its Pharmacological Intervention.ACS pharmacology & translational science · 2022Article
- Atypical U3 snoRNA Suppresses the Process of Pterygium Through Modulating 18S Ribosomal RNA Synthesis.Investigative ophthalmology & visual science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main treatment for pterygium is surgical removal. However, pterygium surgery is concerned with high rates of postoperative recurrence. Predicting factors of recurrence are not fully understood, yet, but they probably depend on a multitude of patient-related, clinical, and/or surgical factors. Several adjuvant treatments have been proposed to reduce postoperative pterygium recurrence, including different antimetabolites, antiangiogenetic factors, and radiation therapy. The purpose of this review is to collect the current evidence regarding application and limits of different therapeutic approaches for preventing postoperative recurrence of pterygium, giving insights and perspectives for better management of this disease. In the light of the current evidence, pterygium surgery cannot disregard wound coverage with conjunctival autografting or rotational flap combined with adjuvant treatments. The rotational flap technique is associated with shorter surgical time rates and prevents graft displacement and necrosis, given its vascular pedicle. Amniotic membrane may still be reserved in case of great conjunctival defects or insufficient conjunctiva. Repeated subconjunctival antivascular endothelial growth factor injections can be considered as an effective and safe adjuvant treatment. Moreover, management of postoperative pain is crucial. Innovative treatment strategies will probably target different molecular pathways, considering recent findings regarding pterygium pathogenesis, to improve better understanding and develop universally shared guidelines. Great importance shall be dedicated to the identification of novel molecular biomarkers and favoring factors of recurrence, in order to achieve a customized surgical treatment for each patient and obtain maximal reduction of postoperative recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.